# Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
Canonical URL: https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-poster-presentations-of-icovamenib-at-the-american-diabetes-association-ada-86th-scientific-sessions
Ticker: BMEA
Company: Biomea Fusion
Source: Biomea Fusion
Published: 2026-05-05 21:51 EST
Original Source URL: https://investors.biomeafusion.com
## Summary

SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that three icovamenib abstracts have been selected for late-breaking poster presentations at the

## Article Body
SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that three icovamenib abstracts have been selected for late-breaking poster presentations at the
## Recent Company News
- 2026-06-03 12:00 EST — [Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-research-collaboration-with-university-of-leicester-to-evaluate-icovamenib-in-combination-with-semaglutide-in-obesity) — Source: Biomea Fusion
- 2026-05-11 20:55 EST — [Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/BMEA/biomea-fusion-reports-first-quarter-2026-financial-results-and-corporate-highlights) — Source: Biomea Fusion
- 2026-05-05 21:51 EST — [Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-poster-presentations-of-icovamenib-at-the-american-diabetes-association-ada-86th-scientific-sessions) — Source: Biomea Fusion
- 2026-04-27 21:37 EST — [Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-positive-52-week-results-from-phase-2-covalent-112-trial-in-type-1-diabetes-showing-c-peptide-improvement-and-durability-following-12-weeks-of-icovamenib-treatment) — Source: Biomea Fusion
- 2026-03-31 11:00 EST — [Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-first-patient-dosed-in-newly-initiated-phase-ii-programs-enrolling-type-2-diabetes-patients-failing-on-standard-of-care-therapies) — Source: Biomea Fusion
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)